Pulmonary Embolism: Mechanism and Therapeutic Innovation

Pulmonary Embolism Clinical Trial

Official title:

Pulmonary Embolism: Mechanism and Therapeutic Innovation

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05360992
• Other study ID #: 2017-I2M-3-003
• Status: Completed
• Start date: January 1, 2017
• Est. completion date: October 13, 2021

Study information

• Verified date: April 2022
• Source: China National Center for Cardiovascular Diseases
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

To explore the pathogenesis, therapy and outcome of pulmonary embolism (PE) and chronic thromboembolic pulmonary hypertension (CTEPH).

Description:

The study recruited consecutive outpatients or hospitalized patients diagnosed with pulmonary embolism (PE cohort) and chronic thromboembolic pulmonary hypertension (CTEPH cohort). The follow-up of all patients was performed annually by phone or outpatient visit. The main outcomes were bleeding, recurrent events, and survival. The objective of the study was to explore the pathogenesis, therapy and outcome of PE and CTEPH.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1200
• Est. completion date: October 13, 2021
• Est. primary completion date: October 13, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• All hospitalized patients or outpatients diagnosed with PE or CTEPH;

• Age =18.

Exclusion Criteria:

• Refused informed consents.

Related Conditions & MeSH terms

• Embolism
• Pulmonary Embolism

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
China National Center for Cardiovascular Diseases

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Recurrent Incidence of Patients	Recurrent PE was measured by computed tomography pulmonary angiography (CTPA) or ventilation/perfusion (V/Q) lung scans. Recurrent deep venous thrombosis was measured by lower extremity Doppler ultrasound.	through study completion, an average of 1 year.
Primary	Bleeding Rate of Patients	Events were recored by follow-up.	through study completion, an average of 1 year.
Primary	Survival Rate of Patients	Events were recored by follow-up.	through study completion, an average of 1 year.